Comparison of Medical and Surgical Treatments of Benign Prostate Hyperplasia in Patients Who Have Low Grade Non Muscle Invasive Bladder Cancer for Tumour Recurrence and Progression

Bladder Cancer Clinical Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02443844
• Other study ID #: 16.02.2015 20/03
• Status: Recruiting
• Phase: Phase 4
• First received: April 28, 2015
• Last updated: May 11, 2015
• Start date: February 2015
• Est. completion date: February 2020

Study information

• Verified date: May 2015
• Source: Diskapi Teaching and Research Hospital
• Contact: Nihat Karakoyunlu, MD
• Phone: 00905324747134
• Email: nkarakoyunlu[@]gmail.com
• Is FDA regulated: No
• Health authority: Turkey: Ministry of Health
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to compare medical and surgical treatments of benign prostate hyperplasia in patients who have non muscle invasive bladder cancer for tumour recurrence and progression.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: February 2020
• Est. primary completion date: February 2018
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 40 Years to 80 Years

Eligibility

Inclusion Criteria:

• Patients who have non muscle invasive bladder cancer male patients patients between 40-80 years old

Exclusion Criteria:

• Patients who have previous prostate surgery Patients who have muscle invasive bladder cancer

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Bladder Cancer
• Prostatic Hyperplasia
• Urinary Bladder Neoplasms

Intervention

Procedure:
• Transurethral Resection
Endoscopic treatment of bladder cancer

Drug:
• Tamsulosin
Medical treatment for benign prostate hyperplasia

Locations

Country	Name	City	State
Turkey	Turkish Ministry of Health Diskapi Yildirim Beyazit Training and Research Hospital	Ankara

Sponsors (1)

Lead Sponsor	Collaborator
Diskapi Teaching and Research Hospital

Country where clinical trial is conducted

Turkey, 

References & Publications (1)

Li S, Zeng XT, Ruan XL, Wang XH, Guo Y, Yang ZH. Simultaneous transurethral resection of bladder cancer and prostate may reduce recurrence rates: A systematic review and meta-analysis. Exp Ther Med. 2012 Oct;4(4):685-692. Epub 2012 Aug 9. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Recurrence	Bladder cancer recurrence rate	3 years	No
Secondary	Progression	Bladder cancer progression rate	3 years	No